GlassScriptPhysician profile
Cecilia S Wang
NPI 1083780753
$5,769.07
in general payments reported to CMS, 2019-2025
30 companies · $1,265 in 2025
The $1,265 reported for 2025 was more than what 84% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $458 · 2020: $553 · 2021: $789 · 2022: $777 · 2023: $859 · 2024: $1,067 · 2025: $1,265.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,082 · Education: $109.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,081.75 |
| Education | $109.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,181.34 | 2021-2025 | Vraylar |
| Otsuka America Pharmaceutical, INC. | $899.23 | 2019-2025 | Rexulti, Nuedexta, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $737.33 | 2020-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $609.24 | 2019-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Takeda Pharmaceuticals U.S.A., INC. | $308.41 | 2020-2025 | Trintellix |
| Janssen Pharmaceuticals, INC | $217.52 | 2019-2025 | Spravato |
| Lundbeck LLC | $209.53 | 2019-2023 | Rexulti |
| Alkermes, INC. | $193.81 | 2021-2025 | Aristada, Lybalvi |
| Merck Sharp & Dohme LLC | $176.60 | 2020-2023 | Belsomra |
| Allergan, INC. | $167.45 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $157.77 | 2019-2022 | |
| Vanda Pharmaceuticals INC. | $132.35 | 2021-2025 | Fanapt, Hetlioz |
| Eisai INC. | $108.70 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $94.56 | 2024-2025 | Cobenfy |
| Bausch Health US, LLC | $91.10 | 2019-2025 | Aplenzin |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neos Therapeutics, LP | $78.81 | 2022-2025 | Exxua |
| Supernus Pharmaceuticals, INC. | $76.18 | 2022-2024 | Qelbree, Qelbree |
| Axsome Therapeutics, INC. | $69.70 | 2023-2024 | Auvelity |
| Validus Pharmaceuticals LLC | $51.44 | 2025 | Equetro, Raldesy |
| Sunovion Pharmaceuticals INC. | $41.78 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $30.25 | 2021-2025 | |
| Orexo US, INC. | $26.37 | 2019-2021 | |
| Owp Pharmaceuticals, INC. | $14.90 | 2021 | |
| Ironshore Pharmaceuticals INC. | $14.70 | 2019 | |
| Almatica Pharma LLC | $14.32 | 2022 | |
| Braeburn INC. | $14.26 | 2024 | Brixadi |
| Idorsia Pharmaceuticals US INC | $13.64 | 2023 | Quviviq |
| Shire North American Group INC | $13.42 | 2019 | |
| Avanir Pharmaceuticals, INC. | $12.56 | 2020 | |
| Indivior INC. | $11.80 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cecilia Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.